Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Small interfering RNA

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: $2,080.0 million Upfront Cash: $60.0 million

            Deal Type: Collaboration March 26, 2020

            Details:

            Companies working together to deliver siRNA molecules to liver, breast, lung and other tissues. Within the first three years of the agreement the parties anticipate starting work on five targets.